OpenAI launches GPT-Rosalind for life sciences research

GPT-Rosalind arrives as OpenAI's first release in a dedicated life sciences model series, aimed at addressing a core bottleneck in drug development. The company notes that progress in life sciences is constrained not only by scientific difficulty but by the complexity of research workflows—fragmented tasks across literature, databases, and experimental data. By supporting multi-step tasks like evidence synthesis, hypothesis generation, and experimental planning, the model targets the earliest stages of discovery, where gains can compound downstream.

The launch uses a controlled approach: qualified U.S. enterprise customers get access through a trusted-access structure with eligibility and governance controls, while a broader Life Sciences research plugin for Codex is freely available. OpenAI is working with major pharma and research organizations, including Amgen and Moderna, and is also partnering with national laboratories like Los Alamos for AI-guided protein and catalyst design.

The model's promise rests on its performance in real scientific settings. Early evaluations show strong results on public benchmarks and against human experts in specific tasks, but the research preview will test whether the model translates into measurable acceleration of discovery in governed, secure environments. The partnerships with established institutions and advisory firms may prove crucial in identifying high-impact use cases and integrating the model into existing workflows.